GlassScriptPhysician profile
Mena M Botros
NPI 1558757104
$2,059.87
in general payments reported to CMS, 2019-2025
14 companies · $403 in 2025
The $403 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2022: $56.69 · 2023: $795 · 2024: $705 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,824 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,824.19 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $599.83 | 2023-2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $436.19 | 2022-2025 | Ofev, Jascayd |
| Actelion Pharmaceuticals US, INC. | $228.46 | 2023 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $188.20 | 2024-2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $178.05 | 2023-2024 | Livtencity, Aralast, Glassia |
| Paragonix Technologies, INC. | $160.04 | 2024 | |
| Genentech USA, INC. | $99.99 | 2019 | |
| Pulmonx Corporation | $53.23 | 2024 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Astellas Pharma US INC | $26.64 | 2025 | Cresemba |
| Grifols USA, LLC | $19.97 | 2023 | Prolastin-C Liquid |
| Sandoz INC. | $19.08 | 2022 | |
| Pharming Healthcare, INC. | $18.82 | 2023 | Ruconest |
| United Therapeutics Corporation | $17.61 | 2022 | |
| Pfizer INC. | $13.76 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mena Botros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.